Cabergoline Tablet IP 0.5 Mg – Cabrovia 0.5 Tablets

Cabrovia 0.5 Tablets –  Cabergoline 0.5mg

Description :
Cabergoline Tablet IP 0.5 Mg contains Cabergoline, a potent ergot-derived dopamine D2 receptor agonist indicated for the treatment of hyperprolactinemia and related reproductive disorders. By selectively stimulating dopamine receptors in the pituitary gland, it suppresses excessive prolactin secretion, thereby normalizing hormonal balance and improving fertility outcomes. Compared to bromocriptine, Cabergoline provides superior efficacy, longer duration of action, and improved tolerability, allowing convenient once- or twice-weekly dosing. It is effective in managing micro- and macroprolactinomas and conditions associated with elevated prolactin levels, ensuring optimal therapeutic response with minimal adverse effects.

Key Benefits:
Potent Dopamine Agonist: Effectively inhibits prolactin release, restoring endocrine and reproductive function.
Long-Acting & Convenient: Extended duration enables once- or twice-weekly dosing, enhancing patient compliance.
Well-Tolerated Profile: Lower risk of gastrointestinal and neurological side effects compared to bromocriptine.

Targeted Specialties:
Endocrinology
Gynecology
Reproductive Medicine / Infertility
Neurology (for pituitary adenoma management)

📢 Disclaimer:
To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.